Company Overview and News

to your dashboard

Headline News

Your Daily Pharma Scoop: Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides Update, Axsome Suffers Setback

2018-01-10 seekingalpha
Today we will discuss the much-anticipated FDA briefing documents for Aradaigm’s (ARDM) Linhaliq. The documents were made available today ahead of the Ad Com meeting on Thursday, January 11th. (332-4)

Are Options Traders Betting on a Big Move in Keryx (KERX) Stock?

2017-11-27 zacks
Investors in Keryx Biopharmaceuticals, Inc. (KERX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 15, 2017 $10 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. (34-1)

Tracking David Abrams' Abrams Capital Management Portfolio - Q3 2017 Update

2017-11-22 seekingalpha
David Abrams’ 13F portfolio increased this quarter from $2.52B to $2.56B. The number of positions decreased from 19 to 18. (701-7)

Tracking Seth Klarman's Baupost Group Holdings - Q3 2017 Update

2017-11-14 seekingalpha
The portfolio continues to be heavily concentrated, with the top three positions accounting for one-third of the 13F portfolio. (514-13)

Corporate News Blog – Keryx Announces FDA Approval of Auryxia for Treatment of Iron Deficiency Anemia Patients with Chronic Kidney Disease

2017-11-09 accesswire
LONDON, UK / ACCESSWIRE / November 9, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) ("Keryx"), following which we have published a free report that can be viewed by signing up at The Company announced on November 07, 2017, that the US Food and Drug Administration (FDA) has approved Auryxia® (Ferric Citrate) Tablets ("Auryxia") for the treatment of iron deficiency anemia in adults with chronic kidney disease (CKD), and not on dialysis. (275-2)

Your Daily Pharma Scoop: Portola Upside, Novartis Reports Positive Cosentyx Data, Keryx Tumbles

2017-11-09 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (482-5)

Keryx (KERX) Q3 Loss Wider Than Expected, Stock Declines

2017-11-08 zacks
Shares of Keryx Biopharmaceuticals Inc. (KERX - Free Report) were down almost 17% on Nov 7 despite receiving FDA approval for a label expansion of its lead drug Auryxia. Lower-than-expected sales of Auryxia in the third quarter led to the selloff. (88-0)

Keryx Biopharmaceuticals, Inc. 2017 Q3 - Results - Earnings Call Slides

2017-11-08 seekingalpha
The following slide deck was published by Keryx Biopharmaceuticals, Inc. in conjunction with their 2017 Q3 earnings call. (10-1)

Keryx Biopharmaceuticals' (KERX) CEO Gregory Madison on Q3 2017 Results - Earnings Call Transcript

2017-11-07 seekingalpha
Good morning. My name is Darla, and I will be your conference operator today. At this time, I would like to welcome everyone to the Keryx Biopharmaceuticals' Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]. Thank you. (10-0)

Keryx FDA Approval For Expanded Indication To Move The Needle

2017-11-07 seekingalpha
Keryx gets FDA approval for expanded indication for patients with chronic kidney disease who are iron deficient. (10-0)

Keryx Biopharmaceuticals FDA Win Outweighed by Q3 Loss

2017-11-07 247wallst
Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) shares took a big step back on Tuesday after the company announced its third-quarter results and an update from the U.S. Food and Drug Administration (FDA). Although the FDA approval was great news, this was not enough to offset disappointing earnings. (10-1)

Keryx (KERX) Posts Wider Q3 Loss, Lags Sales, Shares Down

2017-11-07 zacks
Keryx Biopharmaceuticals Inc. (KERX - Free Report) ) is a Boston-based biopharmaceutical company working in the field of renal diseases. (25-0)

New Strong Sell Stocks for November 7th

2017-11-07 zacks
Tesla, Inc. (TSLA - Free Report) is a designer and seller of electric vehicles and energy storage products. The Zacks Consensus Estimate for its current year earnings has been revised 23.1% downward over the last 30 days. (16-0)

Should You Sell Triton International (TRTN) Before Earnings?

2017-11-07 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Triton International Limited (TRTN - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Triton International is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. (12-0)

Is a Surprise Coming for Aerie (AERI) This Earnings Season?

2017-11-07 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Aerie Pharmaceuticals, Inc. (AERI - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. (20-0)

CUSIP: 492515101